The increasing availability of PET tracers for other pathological targets (tau for Alzheimer’s disease, with more under development for other pathologies) will enable such effects, if present, to be revealed across different therapeutic approaches and neurological disorders. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.